Your browser doesn't support javascript.
loading
Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
Garland, Suzanne M; Anagani, Manjula; Bhatla, Neerja; Chatterjee, Sukanta; Lalwani, Sanjay; Ross, Cecil; Group, Thomas; Lin, Jianxin; Luxembourg, Alain; Walia, Anuj; Tu, Yingmei.
Afiliação
  • Garland SM; Department of Obstetrics and Gynaecology, The University of Melbourne, Parkville, Victoria, Australia.
  • Anagani M; Infection and Immunity, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
  • Bhatla N; Centre for Women's Infectious Diseases Research, The Royal Women's Hospital, Parkville, Victoria, Australia.
  • Chatterjee S; Woman and Child Institute, CARE Super Specialty Hospital & Transplant Centre, Hyderabad, India.
  • Lalwani S; Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
  • Ross C; Department of Pediatrics, KPC Medical College & Hospital, Kolkata, India.
  • Group T; Lalwani Mother & Child Care Hospital, Pune, India.
  • Lin J; Department of Chest Medicine & Hematology, St. John's Medical College Hospital, Bangalore, India.
  • Luxembourg A; Merck & Co., Inc., Rahway, NJ, USA.
  • Walia A; Merck & Co., Inc., Rahway, NJ, USA.
  • Tu Y; Merck & Co., Inc., Rahway, NJ, USA.
Hum Vaccin Immunother ; 18(6): 2105067, 2022 Nov 30.
Article em En | MEDLINE | ID: mdl-35997582

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Papillomavirus / Vacinas contra Papillomavirus Tipo de estudo: Guideline Limite: Adolescent / Child / Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Papillomavirus / Vacinas contra Papillomavirus Tipo de estudo: Guideline Limite: Adolescent / Child / Female / Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article